The Claim
In HIV-infected adults on suppressive antiretroviral therapy, rosuvastatin (10 mg daily for 48 weeks) reduces T cell activation markers independently of changes in LDL cholesterol, indicating an anti-inflammatory effect distinct from lipid-lowering.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with HIV who are on antiretroviral therapy, taking rosuvastatin for 48 weeks at 10 mg daily lowers markers of T cell activation without changing LDL cholesterol levels, showing a direct anti-inflammatory effect.
See the scientific wording
In HIV-infected adults on suppressive antiretroviral therapy, the reduction in T cell activation markers by rosuvastatin (10 mg daily for 48 weeks) is independent of changes in LDL cholesterol, suggesting an anti-inflammatory effect distinct from lipid-lowering.
Rosuvastatin blocks a key enzyme in cholesterol production, which also stops the creation of molecules that activate inflammatory proteins inside immune cells. This reduces the release of inflammatory signals from monocytes, which in turn calms down overactive T cells and lowers their activation markers without changing cholesterol levels.
What the research says
1 studyRosuvastatin helped calm the overactive immune system in people with HIV, even though it didn’t change their cholesterol levels — meaning it worked by reducing inflammation, not by lowering fats.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.